Neuronetics STIM 深 沪
已收盘 02-06 16:00:00 美东时间
1.56
+0.140
+9.86%
华盛通- 最 高1.60
- 今 开1.44
- 成交量 177.39万股
- 最 低 1.44
- 昨 收 1.42
- 总市值 1.07亿
- 52周最高 5.92
- 市盈率 静 --
- 换手率 2.59%
- 52周最低 1.25
- 委 比 -25.47%
- 总股本 6848.59万
- 历史最高 39.39
- 量 比 1.01
- 振 幅 11.27%
- 历史最低 0.52
- 每 手 1
- 风险率 1.06%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Neuronetics Amends Credit Agreement With Perceptive Credit Holdings
Neuronetics Amends Credit Agreement With Perceptive Credit Holdings Neuronetics Inc. has announced an amendment to its existing credit agreement with Perceptive Credit Holdings IV, LP and other lenders. The amendment, effective January 15, 2026, modifies the requirements for subsidiaries joining as
01-22 20:31
Neuronetics Grants Retention-Focused Incentive Awards to Executives
The latest update is out from Neuronetics ( ($STIM) ). On December 30, 2025, Ne...
01-07 06:30
Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare Conference
Neuronetics, Inc. announced that its management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025. The company, a leader in neurohealth therapies, provides non-drug treatments for mental health conditions, including NeuroStar Advanced Therapy, which has delivered over 7.4 million treatments for major depressive disorder (MDD). The therapy is FDA-cleared and supported by extensive c...
2025-11-20 13:30
TRICARE West Expands NeuroStar® TMS Coverage to Include Adolescents Aged 15+ Struggling with Depression
Neuronetics announces TRICARE policy expansion to include TMS for adolescents aged 15 and older across 26 states, providing a non-drug depression treatment option for children of military families, supported by clinical evidence and FDA clearance.
2025-11-12 15:33
Neuronetics Sees Q4 Sales $40.000M-$43.000M vs $43.057M Est
Neuronetics (NASDAQ:STIM) sees Q4 sales of $40.000 million-$43.000 million vs $43.057 million analyst estimate.
2025-11-04 20:08
Neuronetics Q3 EPS $(0.13) Misses $(0.10) Estimate, Sales $37.297M Miss $38.055M Estimate
Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.10) by 26.21 percent. This is a 70.45 percent increase over losses of $(0.44) per share from the
2025-11-04 20:06
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neuronetics, Inc. has granted inducement awards in the form of restricted stock units (RSUs) to twelve new employees. The awards, totaling 1,500 RSUs each for most employees, with some receiving higher amounts, were approved by the company’s Compensation Committee as a material inducement to their employment. The RSUs vest over three years, contingent on continued employment through each vesting date, and are subject to the terms of the company’s...
2025-10-31 20:30
Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand NeuroStar Access and Operational Excellence
Neuronetics and Elite DNA Behavioral Health have entered a three-year exclusive agreement making Neuronetics the sole provider of transcranial magnetic stimulation (TMS) devices across Elite DNA’s 30+ locations. The collaboration includes expanded fee-based services like patient support, consultations, and scheduling, leveraging Neuronetics’ Greenbrook platform to enhance efficiency and patient care. The partnership aims to expand access to life-...
2025-10-30 12:32
Neuronetics to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call
Neuronetics, Inc. announced it will release third quarter 2025 financial and operating results before the market opens on November 4, 2025, followed by a conference call at 8:30 a.m. ET. The call will be webcast at https://edge.media-server.com/mmc/p/yxrs8osc and participants can register by phone in advance. Neuronetics, a global leader in neuroscience, offers NeuroStar Advanced Therapy, a non-invasive treatment for neurohealth conditions, and o...
2025-10-21 12:30
New York Medicaid To Cover Neuronetics' TMS Therapy For Major Depressive Disorder Starting October 2025
Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of
2025-09-17 20:41
